<p>Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX - 獲取免費報告）週四股價上漲 6.1%。該股最高交易價為 32.00 美元，最後交易價為 31.64 美元。在交易中，共成交 64,228 股，較 374,984 股的平均交易量下降了 83%。該股此前收盤價為 29.83 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>PRAX 近期成為多份研究報告的主題。Truist Financial 將 Praxis Precision Medicines 的目標股價從 175.00 美元下調至 85.00 美元，並在 3 月 3 日的研究報告中給予該公司 “買入” 評級。Needham &amp; Company LLC 在 4 月 8 日的研究報告中重申了 “買入” 評級，並對 Praxis Precision Medicines 的目標股價設定為 85.00 美元。Robert W. Baird 在 3 月 3 日的研究報告中將 Praxis Precision Medicines 的目標股價從 117.00 美元下調至 73.00 美元，並給予該公司 “跑贏大盤” 評級。Wedbush 在 2 月 28 日的研究報告中將 Praxis Precision Medicines 的評級從 “持有” 下調至 “強烈賣出”。最後，HC Wainwright 在 3 月 3 日的研究報告中將 Praxis Precision Medicines 的目標股價從 120.00 美元下調至 105.00 美元，並對該股給予 “買入” 評級。一位研究分析師對該股給予了 “賣出” 評級，八位分析師對該公司的股票給予了 “買入” 評級。根據 MarketBeat.com 的數據，Praxis Precision Medicines 目前的共識評級為 “適度買入”，平均目標股價為 123.33 美元。</p>
<p><strong>查看我們對 PRAX 的最新股票分析</strong></p>
<h2>Praxis Precision Medicines 股價上漲 4.4%</h2>
<p>該公司 50 日簡單移動平均線為 47.34 美元，200 日簡單移動平均線為 64.42 美元。公司的市值為 6.2778 億美元，市盈率為-3.02，貝塔值為 2.66。</p>
<p>Praxis Precision Medicines（納斯達克代碼：PRAX - 獲取免費報告）最近於 2 月 28 日發佈了季度財報。該公司報告季度每股收益為（2.94 美元），低於市場共識預期的（2.76 美元）0.18 美元。該公司季度收入為 748 萬美元，而分析師預期為 36 萬美元。Praxis Precision Medicines 的股本回報率為-54.86%，淨利潤率為-9,409.22%。股票研究分析師預測，Praxis Precision Medicines, Inc.在當前財政年度將發佈-10.22 美元的每股收益。</p>
<h2>Praxis Precision Medicines 的機構交易</h2>
<p>大型投資者最近買入和賣出了該公司的股票。GF Fund Management CO. LTD.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 48,000 美元。Graham Capital Management L.P.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 209,000 美元。KLP Kapitalforvaltning AS 在第四季度新購入 Praxis Precision Medicines 的股份，價值約 215,000 美元。最後，Envestnet Asset Management Inc.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 231,000 美元。機構投資者和對沖基金持有該公司 67.84% 的股份。</p>
<h2>Praxis Precision Medicines 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Praxis Precision Medicines, Inc.是一家臨牀階段的生物製藥公司，專注於開發治療中樞神經系統疾病的療法，這些疾病的特徵是神經元興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行針對特發性震顫的第三階段臨牀試驗；PRAX-562 用於治療患有發育性和癲癇性腦病（DEE）的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
<h2>瞭解更多</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Praxis Precision Medicines</li>
<li>使用 MarketBeat 股票拆分計算器</li>
<li>關税豁免為台灣半導體的反彈鋪平道路</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>緩解關税：三隻股票將從美元貶值中受益</li>
<li>什麼使一隻股票成為優質分紅股？</li>
<li>博通與蘋果的關係：人工智能機會與關税風險相遇</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於 Praxis Precision Medicines 嗎？</h2>
<p>在你考慮 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Praxis Precision Medicines 並不在名單上。</p>
<p>雖然 Praxis Precision Medicines 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

PRAX

<p>Praxis Precision Medicines（納斯達克代碼：PRAX）股價上漲 6.1%，至 31.64 美元，儘管交易量大幅下降。分析師的評級不一，目標價格範圍從 73 美元到 175 美元不等。該公司報告的季度每股收益為-2.94 美元，未能達到預期，市值為 6.2778 億美元。機構投資者持有 67.84% 的股份。Praxis 專注於開發中樞神經系統疾病的治療方案，目前有多個候選藥物處於臨牀試驗階段</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) shares shot up 6.1% on Thursday . The stock traded as high as $32.00 and last traded at $31.64. 64,228 shares changed hands during trading, a decline of 83% from the average session volume of 374,984 shares. The stock had previously closed at $29.83.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（納斯達克代碼：PRAX - 獲取免費報告）週四股價上漲 6.1%。該股最高交易價為 32.00 美元，最後交易價為 31.64 美元。在交易中，共成交 64,228 股，較 374,984 股的平均交易量下降了 83%。該股此前收盤價為 29.83 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>PRAX has been the subject of several recent research reports. Truist Financial decreased their price target on shares of Praxis Precision Medicines from $175.00 to $85.00 and set a &#34;buy&#34; rating for the company in a research report on Monday, March 3rd. Needham &amp; Company LLC reiterated a &#34;buy&#34; rating and issued a $85.00 price objective on shares of Praxis Precision Medicines in a research note on Tuesday, April 8th. Robert W. Baird decreased their price objective on shares of Praxis Precision Medicines from $117.00 to $73.00 and set an &#34;outperform&#34; rating for the company in a research report on Monday, March 3rd. Wedbush downgraded shares of Praxis Precision Medicines from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, February 28th. Finally, HC Wainwright cut their price target on Praxis Precision Medicines from $120.00 to $105.00 and set a &#34;buy&#34; rating on the stock in a research note on Monday, March 3rd. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat.com, Praxis Precision Medicines presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $123.33.</p>
<div class="lb-trans"><p>PRAX 近期成為多份研究報告的主題。Truist Financial 將 Praxis Precision Medicines 的目標股價從 175.00 美元下調至 85.00 美元，並在 3 月 3 日的研究報告中給予該公司 “買入” 評級。Needham &amp; Company LLC 在 4 月 8 日的研究報告中重申了 “買入” 評級，並對 Praxis Precision Medicines 的目標股價設定為 85.00 美元。Robert W. Baird 在 3 月 3 日的研究報告中將 Praxis Precision Medicines 的目標股價從 117.00 美元下調至 73.00 美元，並給予該公司 “跑贏大盤” 評級。Wedbush 在 2 月 28 日的研究報告中將 Praxis Precision Medicines 的評級從 “持有” 下調至 “強烈賣出”。最後，HC Wainwright 在 3 月 3 日的研究報告中將 Praxis Precision Medicines 的目標股價從 120.00 美元下調至 105.00 美元，並對該股給予 “買入” 評級。一位研究分析師對該股給予了 “賣出” 評級，八位分析師對該公司的股票給予了 “買入” 評級。根據 MarketBeat.com 的數據，Praxis Precision Medicines 目前的共識評級為 “適度買入”，平均目標股價為 123.33 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on PRAX</strong></p>
<div class="lb-trans"><p><strong>查看我們對 PRAX 的最新股票分析</strong></p>
</div><h2>Praxis Precision Medicines Stock Up 4.4 %</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股價上漲 4.4%</h2>
</div><p>The firm has a fifty day simple moving average of $47.34 and a 200-day simple moving average of $64.42. The company has a market cap of $627.78 million, a PE ratio of -3.02 and a beta of 2.66.</p>
<div class="lb-trans"><p>該公司 50 日簡單移動平均線為 47.34 美元，200 日簡單移動平均線為 64.42 美元。公司的市值為 6.2778 億美元，市盈率為-3.02，貝塔值為 2.66。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last released its quarterly earnings results on Friday, February 28th. The company reported ($2.94) EPS for the quarter, missing the consensus estimate of ($2.76) by ($0.18). The firm had revenue of $7.48 million for the quarter, compared to analyst estimates of $0.36 million. Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. Equities research analysts forecast that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（納斯達克代碼：PRAX - 獲取免費報告）最近於 2 月 28 日發佈了季度財報。該公司報告季度每股收益為（2.94 美元），低於市場共識預期的（2.76 美元）0.18 美元。該公司季度收入為 748 萬美元，而分析師預期為 36 萬美元。Praxis Precision Medicines 的股本回報率為-54.86%，淨利潤率為-9,409.22%。股票研究分析師預測，Praxis Precision Medicines, Inc.在當前財政年度將發佈-10.22 美元的每股收益。</p>
</div><h2>Institutional Trading of Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 的機構交易</h2>
</div><p>Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new stake in shares of Praxis Precision Medicines during the fourth quarter worth about $30,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Praxis Precision Medicines during the 4th quarter worth approximately $48,000. Graham Capital Management L.P. purchased a new position in shares of Praxis Precision Medicines in the 4th quarter valued at approximately $209,000. KLP Kapitalforvaltning AS acquired a new position in shares of Praxis Precision Medicines in the fourth quarter valued at approximately $215,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Praxis Precision Medicines during the fourth quarter worth approximately $231,000. Institutional investors and hedge funds own 67.84% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近買入和賣出了該公司的股票。GF Fund Management CO. LTD.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 30,000 美元。Mirae Asset Global Investments Co. Ltd.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 48,000 美元。Graham Capital Management L.P.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 209,000 美元。KLP Kapitalforvaltning AS 在第四季度新購入 Praxis Precision Medicines 的股份，價值約 215,000 美元。最後，Envestnet Asset Management Inc.在第四季度新購入 Praxis Precision Medicines 的股份，價值約 231,000 美元。機構投資者和對沖基金持有該公司 67.84% 的股份。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.是一家臨牀階段的生物製藥公司，專注於開發治療中樞神經系統疾病的療法，這些疾病的特徵是神經元興奮 - 抑制失衡。該公司正在開發 ulixacaltamide，這是一種 T 型鈣通道的小分子抑制劑，目前正在進行針對特發性震顫的第三階段臨牀試驗；PRAX-562 用於治療患有發育性和癲癇性腦病（DEE）的兒童患者；以及 PRAX-628 用於治療局灶性癲癇。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>Mitigating Tariffs: 3 Stocks to Gain From a Weaker U.S. Dollar</li>
<li>What Makes a Stock a Good Dividend Stock?</li>
<li>Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Praxis Precision Medicines</li>
<li>使用 MarketBeat 股票拆分計算器</li>
<li>關税豁免為台灣半導體的反彈鋪平道路</li>
<li>你應該將這些沃倫·巴菲特的股票加入你的投資組合嗎？</li>
<li>緩解關税：三隻股票將從美元貶值中受益</li>
<li>什麼使一隻股票成為優質分紅股？</li>
<li>博通與蘋果的關係：人工智能機會與關税風險相遇</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送電子郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 Praxis Precision Medicines 嗎？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Praxis Precision Medicines 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Praxis Precision Medicines 並不在名單上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Praxis Precision Medicines 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Praxis Precision Medicines (NASDAQ:PRAX) 的股價上漲了 6.1% - 你是否應該購買？